{
  "id": "resp_0515a5a2b9476e6000693c8d6ae6d08194b744cbc92478b9c7",
  "object": "response",
  "created_at": 1765576043,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_0515a5a2b9476e6000693c8d6c105c8194bf165339f54d6a43",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0515a5a2b9476e6000693c8d6d89f881948275e865b06b65fd",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"CDK12 inhibitor\" NCT0 \"triple-negative breast\""
      }
    },
    {
      "id": "rs_0515a5a2b9476e6000693c8d706fd48194933944e7e9a4def4",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0515a5a2b9476e6000693c8d74ed108194a1207868118407b7",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "dinaciclib olaparib triple-negative breast cancer NCT0"
      }
    },
    {
      "id": "rs_0515a5a2b9476e6000693c8d776ab88194881cbe5a33756bf9",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0515a5a2b9476e6000693c8d7c04fc81948b462db076e7f63a",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "ClinicalTrials.gov dinaciclib triple-negative breast NCT"
      }
    },
    {
      "id": "rs_0515a5a2b9476e6000693c8d7e228c8194a2a541a3f9b05a8d",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0515a5a2b9476e6000693c8d9248dc8194bba2d89c67f76d3b",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://pubmed.ncbi.nlm.nih.gov/31668947/"
      }
    },
    {
      "id": "rs_0515a5a2b9476e6000693c8d944c0081949d9c4646990655f5",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0515a5a2b9476e6000693c8d9536508194b1726d5c0b473554",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "dinaciclib",
        "url": "https://pubmed.ncbi.nlm.nih.gov/27880910/"
      }
    },
    {
      "id": "rs_0515a5a2b9476e6000693c8d998ad881948673e717835d640e",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0515a5a2b9476e6000693c8d99d6348194b292ff7921a2751a",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://pubmed.ncbi.nlm.nih.gov/25947565/"
      }
    },
    {
      "id": "rs_0515a5a2b9476e6000693c8d9b9a84819491d56cb0daa4d75d",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0515a5a2b9476e6000693c8d9d733c8194bd8855cb78ae43c1",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "##  Abstract",
        "url": "https://pubmed.ncbi.nlm.nih.gov/37478560/"
      }
    },
    {
      "id": "rs_0515a5a2b9476e6000693c8da085148194b90d2763833fa59a",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0515a5a2b9476e6000693c8dba72a08194a062a2c22dc65e88",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrials.gov NCT01676753 dinaciclib pembrolizumab triple negative breast"
      }
    },
    {
      "id": "rs_0515a5a2b9476e6000693c8dbea4a881948d8f1fd47dafc509",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0515a5a2b9476e6000693c8dc487888194afa15fbf873edf40",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://cdek.pharmacy.purdue.edu/trial/NCT01676753/"
      }
    },
    {
      "id": "rs_0515a5a2b9476e6000693c8dc77f548194bf596886f7624691",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_0515a5a2b9476e6000693c8ddbacd08194be00350c0c7af53f",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [
            {
              "type": "url_citation",
              "end_index": 192,
              "start_index": 122,
              "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/31668947/"
            },
            {
              "type": "url_citation",
              "end_index": 405,
              "start_index": 335,
              "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/31668947/"
            },
            {
              "type": "url_citation",
              "end_index": 558,
              "start_index": 488,
              "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/31668947/"
            },
            {
              "type": "url_citation",
              "end_index": 827,
              "start_index": 757,
              "title": "CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27880910/"
            },
            {
              "type": "url_citation",
              "end_index": 1037,
              "start_index": 967,
              "title": "CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27880910/"
            },
            {
              "type": "url_citation",
              "end_index": 1197,
              "start_index": 1127,
              "title": "CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/27880910/"
            },
            {
              "type": "url_citation",
              "end_index": 1475,
              "start_index": 1405,
              "title": "CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/38574883/"
            },
            {
              "type": "url_citation",
              "end_index": 1620,
              "start_index": 1550,
              "title": "CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/38574883/"
            },
            {
              "type": "url_citation",
              "end_index": 1796,
              "start_index": 1726,
              "title": "CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/38574883/"
            },
            {
              "type": "url_citation",
              "end_index": 2055,
              "start_index": 1985,
              "title": "Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/"
            },
            {
              "type": "url_citation",
              "end_index": 2226,
              "start_index": 2156,
              "title": "Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/"
            },
            {
              "type": "url_citation",
              "end_index": 2444,
              "start_index": 2374,
              "title": "Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/"
            },
            {
              "type": "url_citation",
              "end_index": 2712,
              "start_index": 2642,
              "title": "Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/37478560/"
            },
            {
              "type": "url_citation",
              "end_index": 2899,
              "start_index": 2829,
              "title": "Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/37478560/"
            },
            {
              "type": "url_citation",
              "end_index": 3121,
              "start_index": 3051,
              "title": "Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/37478560/"
            },
            {
              "type": "url_citation",
              "end_index": 3417,
              "start_index": 3347,
              "title": "A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25947565/"
            },
            {
              "type": "url_citation",
              "end_index": 3559,
              "start_index": 3489,
              "title": "A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25947565/"
            },
            {
              "type": "url_citation",
              "end_index": 3695,
              "start_index": 3625,
              "title": "A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/25947565/"
            },
            {
              "type": "url_citation",
              "end_index": 3862,
              "start_index": 3781,
              "title": "\n\n    \n        Trial | NCT01676753\n    \n\n",
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT01676753/"
            },
            {
              "type": "url_citation",
              "end_index": 3976,
              "start_index": 3895,
              "title": "\n\n    \n        Trial | NCT01676753\n    \n\n",
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT01676753/"
            },
            {
              "type": "url_citation",
              "end_index": 4149,
              "start_index": 4068,
              "title": "\n\n    \n        Trial | NCT01676753\n    \n\n",
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT01676753/"
            },
            {
              "type": "url_citation",
              "end_index": 4266,
              "start_index": 4185,
              "title": "\n\n    \n        Trial | NCT01676753\n    \n\n",
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT01676753/"
            }
          ],
          "logprobs": [],
          "text": "- **Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer** — `https://pubmed.ncbi.nlm.nih.gov/31668947/` ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31668947/))  \n  - “SR-4835, a highly selective dual inhibitor of **CDK12** and **CDK13**, which disables **triple-negative breast cancer (TNBC)** cells.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31668947/))  \n  - “promoting synergy with DNA-damaging chemotherapy and **PARP inhibitors**.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31668947/))  \n\n- **CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer** — `https://pubmed.ncbi.nlm.nih.gov/27880910/` ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27880910/))  \n  - “**dinaciclib**, an inhibitor of cyclin-dependent kinases (CDKs) 1, 2, 5, and 9, additionally has potent activity against **CDK12**” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27880910/))  \n  - “support the broad use of combined **CDK12** and **PARP inhibition** in **TNBC**.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27880910/))  \n\n- **CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer** — `https://pubmed.ncbi.nlm.nih.gov/38574883/` ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38574883/))  \n  - “the broad range **dinaciclib** and the **CDK12-specific SR-4835**” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38574883/))  \n  - “both CDKis showed synergism with **olaparib**, as well as with **cisplatin** and **gemcitabine**” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38574883/))  \n\n- **Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor** — `https://pubmed.ncbi.nlm.nih.gov/34864331/` ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34864331/))  \n  - “a potent **PROTAC degrader PP-C8** based on the noncovalent dual inhibitors of **CDK12/13**” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34864331/))  \n  - “**PP-C8** demonstrates profound synergistic antiproliferative effects with **PARP inhibitor** in **triple-negative breast cancer (TNBC)**.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34864331/))  \n\n- **Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer** — `https://pubmed.ncbi.nlm.nih.gov/37478560/` ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37478560/))  \n  - “a series of small molecule inhibitors targeting both **CDK12** and **PARP1** were designed and synthesized.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37478560/))  \n  - “The new dual-target inhibitor (**12e**) showed potent inhibitory activity against **CDK12 (IC_{50} = 285 nM)** and **PARP1 (IC_{50} = 34 nM)**” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37478560/))  \n\n- **A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer** — `https://pubmed.ncbi.nlm.nih.gov/25947565/` ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25947565/))  \n  - “**dinaciclib (SCH 727965)** in combination with **epirubicin**” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25947565/))  \n  - “Trial registration:  ClinicalTrials.gov **NCT01624441**.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25947565/))  \n\n- **Trial | NCT01676753** — `https://cdek.pharmacy.purdue.edu/trial/NCT01676753/` ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT01676753/))  \n  - “Trial | **NCT01676753**” ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT01676753/))  \n  - “Phase 1b Trial of **Dinaciclib** With **Pembrolizumab** for Advanced Breast Cancer” ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT01676753/))  \n  - “Other names: **SCH727965**” ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT01676753/))"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "medium",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 44857,
    "input_tokens_details": {
      "cached_tokens": 4352
    },
    "output_tokens": 7633,
    "output_tokens_details": {
      "reasoning_tokens": 6480
    },
    "total_tokens": 52490
  },
  "user": null,
  "metadata": {}
}